Bafna Pharmaceuticals Ltd Financials
Company Logo

Bafna Pharmaceuticals Ltd Financial Statement

Bafna Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue33.79
Operating Expense32.42
Net Profit-0.72
Net Profit Margin-2.13
Earning Per Share-0.31
EBIDTA1.37
Effective Tax RateTBA

Bafna Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual152.47
Operating Expenses Annual141.35
Operating Profit Annual14.63
Interest Annual2.29
Depreciation5.00
Net Profit Annual7.35
Tax AnnualTBA

Bafna Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning7.81
Cash Flow from Operations9.48
Cash Flow from Investing-15.05
Cash Flow from Financing-0.85
Cash Flow at the End1.40

Bafna Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)9.60
PBIT Margin (%)6.32
PBT Margin (%)3.56
Net PROFIT Margin (%)4.82
Return On Networth / Equity (%)5.74
Return On Networth /Employed (%)6.29
Return On Assets (%)7.18
Total Debt / Equity (X)0.31
Asset Turnover Ratio (%)1.49

Bafna Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual41.98
Total Current Assets Annual94.47
Non Current Assets Annual53.21
Total Shareholders Funds Annual80.84
Total Assets Annual147.68

Bafna Pharmaceuticals Ltd Earning Calls

EPS (INR)

Expected

0.00

Reported

-0.25

Surprise

0.00%

Jun 2019

EPS beaten by 0.00%

Sep 2018

EPS beaten by 0.00%

Jun 2018

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 5, 2024, Bafna Pharmaceuticals Ltd has a market capitalization of 181.35 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Bafna Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.30.
In FY 2023 , Bafna Pharmaceuticals Ltd recorded a total revenue of approximately 152.47 Cr marking a significant milestone in the company's financial performance.
Bafna Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.3% and 0.3% annually, respectively..
Bafna Pharmaceuticals Ltd's current PE ratio is 24.67.
Bafna Pharmaceuticals Ltd's ROCE averaged 11.4% from the FY ending March 2022 to 2024, with a median of 11.1%. It peaked at 14.0% in March 2023, reflecting strong capital efficiency over the period..
Bafna Pharmaceuticals Ltd's latest EBIT is Rs. 9.64 Cr, surpassing the average EBIT of Rs. 9.77 Cr over the 5 years..